Similar articles

• Amino acid-conferred resistance to melphalan. I. Structure-activity relationship in cultured murine L1210 leukemia cells.

  Vistica DT, Toal JN, Rabinovitz M. Vistica DT, et al. Cancer Treat Rep. 1976 Sep;60(9):1363-7. Cancer Treat Rep. 1976. PMID: 1016969
• Amino acid-conferred protection against melphalan--characterization of melphalan transport and correlation of uptake with cytotoxicity in cultured L1210 murine leukemia cells.

  Vistica DT, Toal JN, Rabinovitz M. Vistica DT, et al. Biochem Pharmacol. 1978;27(24):2865-70. doi: 10.1016/0006-2952(78)90202-2. Biochem Pharmacol. 1978. PMID: 736979 No abstract available.
• Amino acid conferred protection against melphalan: comparison of amino acids which reduce melphalan toxicity to murine bone marrow precursor cells (CFU-C) and murine L1210 leukemia cells.

  Vistica DT, Rabon A, Rabinovitz M. Vistica DT, et al. Res Commun Chem Pathol Pharmacol. 1979 Jan;23(1):171-83. Res Commun Chem Pathol Pharmacol. 1979. PMID: 441510
• Cellular pharmacokinetics of the phenylalanine mustards.

  Vistica DT. Vistica DT. Pharmacol Ther. 1983;22(3):379-406. doi: 10.1016/0163-7258(83)90009-8. Pharmacol Ther. 1983. PMID: 6361804 Review. No abstract available.
• L-phenylalanine mustard (L-PAM): the first 25 years.

  Furner RL, Brown RK. Furner RL, et al. Cancer Treat Rep. 1980 Apr-May;64(4-5):559-74. Cancer Treat Rep. 1980. PMID: 7000345 Review. No abstract available.